 VANCOUVER, Washington, May 20, 2021 GLOBE NEWSWIRE -- CytoDyn Inc. OTC.QB: CYDY, CytoDyn or the Company, a late-stage biotechnology company developing VyrologixTM leronlimab-PRO 140, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today the promotion of Antonio Migliarese to Chief Financial Officer of the Company. Mr. Migliarese joined CytoDyn in January 2020, and previously served as Vice President, Corporate Controller. 